The GV-backed genomic editing technology developer has filed to raise up to $100m, adding to some $225m of venture funding in under three years.

US-based genetic therapy developer Beam Therapeutics has filed for a $100m initial public offering that would enable internet and technology group Alphabet and gene editing technology producer Editas to exit. Beam is working on genetic medicines for serious diseases, using its genomic base editing platform to target point mutations, which it claims are responsible for…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.